52241 Secukinumab demonstrates low immunogenicity in patients with moderate-to-severe hidradenitis suppurativa: Results from placebo-controlled, double-blind, Phase 3 SUNSHINE and SUNRISE trials - 02/09/24
Doi : 10.1016/j.jaad.2024.07.342
Martina Porter
Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS)
Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Alexa B. Kimball
Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS)
Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Il testo completo di questo articolo è disponibile in PDF.
| Commercial Support: Study is 100% sponsored by Novartis Pharma AG. |
© 2024
Pubblicato da Elsevier Masson SAS.
Vol 91 - N° 3S
P. AB84 - settembre 2024 Ritorno al numero
Articolo precedente
- 50546 Secondary intention healing of surgical wounds in the dorsal hand: an under-utilized technique?
- Siwaporn Hiranput, Paul Devakar Yesudian, Periasamy Balasubramaniam
- 54626 Segmentation of Melanoma Dermoscopic Features using Deep Learning
- Scott Heston, Tarek Dawamne, Ibeth Caceres, Maleeha Ahmad, Sahil Sinha, Abigail Medford, Kirthana Rao, Michael Biskup, Theresa Thurston, Benjamin Garcia
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?